Alpine Woods Capital Investors LLC cut its position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,450 shares of the company’s stock after selling 100 shares during the period. Alpine Woods Capital Investors LLC’s holdings in Acadia Healthcare were worth $319,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ACHC. DekaBank Deutsche Girozentrale purchased a new stake in Acadia Healthcare during the first quarter worth about $3,240,000. Falcon Point Capital LLC purchased a new stake in Acadia Healthcare during the first quarter worth about $16,792,000. Monarch Partners Asset Management LLC purchased a new stake in Acadia Healthcare during the first quarter worth about $16,079,000. Jennison Associates LLC increased its stake in Acadia Healthcare by 6.3% in the first quarter. Jennison Associates LLC now owns 885,116 shares of the company’s stock worth $38,591,000 after buying an additional 52,158 shares during the last quarter. Finally, Emerald Advisers Inc. PA increased its stake in Acadia Healthcare by 2.3% in the first quarter. Emerald Advisers Inc. PA now owns 85,198 shares of the company’s stock worth $3,715,000 after buying an additional 1,876 shares during the last quarter.
Acadia Healthcare Company, Inc. (NASDAQ ACHC) opened at 46.90 on Friday. Acadia Healthcare Company, Inc. has a 12-month low of $32.54 and a 12-month high of $54.34. The stock has a market cap of $4.12 billion, a PE ratio of 515.38 and a beta of 1.15. The company’s 50-day moving average price is $50.51 and its 200-day moving average price is $45.06.
Acadia Healthcare (NASDAQ:ACHC) last posted its earnings results on Thursday, July 27th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $715.90 million during the quarter, compared to analysts’ expectations of $717.38 million. Acadia Healthcare had a return on equity of 8.69% and a net margin of 0.30%. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 earnings per share. On average, equities analysts expect that Acadia Healthcare Company, Inc. will post $2.45 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/19/alpine-woods-capital-investors-llc-cuts-stake-in-acadia-healthcare-company-inc-achc.html.
A number of analysts have issued reports on the company. UBS AG reaffirmed a “positive” rating and issued a $60.00 price objective (up previously from $54.00) on shares of Acadia Healthcare in a research note on Monday, July 31st. Craig Hallum reiterated a “buy” rating and issued a $65.00 target price (up previously from $52.00) on shares of Acadia Healthcare in a report on Monday, July 31st. Deutsche Bank AG lifted their target price on Acadia Healthcare from $58.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, July 31st. BidaskClub cut Acadia Healthcare from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Zacks Investment Research cut Acadia Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $59.21.
In other Acadia Healthcare news, Director Reeve B. Waud sold 50,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $45.09, for a total transaction of $2,254,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Grieco sold 2,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $51.71, for a total value of $103,420.00. Following the sale, the director now directly owns 45,013 shares of the company’s stock, valued at approximately $2,327,622.23. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,138,347 shares of company stock valued at $105,486,669. 11.10% of the stock is owned by insiders.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Want to see what other hedge funds are holding ACHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acadia Healthcare Company, Inc. (NASDAQ:ACHC).
Receive News & Ratings for Acadia Healthcare Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
